Lilly’s CEO Lechleiter Plans Surgery for Dilated Artery

Eli Lilly & Co. (LLY) said John Lechleiter, the drugmaker’s chairman and chief executive officer, will undergo surgery for a dilated aorta, an asymptomatic condition from which he is expected to recover.

Lechleiter, 59, is scheduled to have surgery May 13 to fix the condition that was caught on an unrelated exam, the Indianapolis-based company said in a statement. He is expected to return to work in several months, Lilly said in the statement.

“It is a serious situation but it has been caught early enough,” Edward Sagebiel, a Lilly spokesman, said yesterday in a telephone interview. “He is expected to make a full recovery.”

In Lechleiter’s absence, Chief Financial Officer Derica Rice will serve as acting CEO and Ellen R. Marram, Lilly’s lead independent director who has been on the board since 2002, will serve as acting chairman, the company said.

A dilated aorta is a bulge or ballooning of the large artery that carries blood from the heart through the chest and abdomen, according to the National Institutes of Health. The condition can often develop before causing any symptoms.

To contact the reporter on this story: Robert Langreth in New York at rlangreth@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.